BAETEN DOMINIQUE ET AL: "Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.", THE NEW ENGLAND JOURNAL OF MEDICINE 24 DEC 2015, vol. 373, no. 26, 24 December 2015 (2015-12-24), pages 2534-2548, ISSN: 1533-4406 (B1)

BARALIAKOS XENOFON ET AL: "Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging", ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, WILEY INTERSCIENCE, US, vol. 63, no. 10, Suppl. S, 1 November 2011 (2011-11-01), page S972, XP009170121, ISSN: 0004-3591 (B1)

Dominique Baeten et al: "L7 - The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Showed Good Safety and Efficacy in the Treatment of Active Ankylosing Spondylitis.", LATE-BREAKING ABSTRACTS: AMERICAN COLLEGE OF RHEUMATOLOGY 2010 ANNUAL SCIENTIFIC MEETING , 30 November 2010 (2010-11-30), XP002761818, Retrieved from the Internet: URL:http://onlinelibrary.wiley.com/doi/10. 1002/art.30132/pdf [retrieved on 2016-09-14] (B1)

ERIK LUBBERTS: "Th17 cytokines and arthritis", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER, BERLIN, DE, vol. 32, no. 1, 4 February 2010 (2010-02-04), pages 43-53, XP019800827, ISSN: 1863-2300 (B1)

WO-A1-2006/013107 (B1)

McInnes: "Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.", Arthritis & Rheumatism, Volume 63,November 2011 Abstract Supplement , October 2010 (2010-10), XP002761820, Retrieved from the Internet: URL:http://www.blackwellpublishing.com/acr meeting/abstract.asp?MeetingID=781&id=9552 5 [retrieved on 2016-09-14] (B1)

Novartis: "View of NCT00809159 on 2010_06_22", ClinicalTrials.gov archive , 22 June 2010 (2010-06-22), XP002761819, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 00809159/2010_06_22 [retrieved on 2016-09-07] (B1)

Novartis: "View of NCT00809614 on 2010_04_29", ClinicalTrials.gov archive , 29 April 2010 (2010-04-29), XP002761821, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 00809614/2010_04_29 [retrieved on 2016-09-14] (B1)

MARK GENOVESE ET AL: "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: Results of a phase IIb study", ARTHRITIS & RHEUMATISM; ABSTRACTS OF THE AMERICAN COLLEGE OF RHEUMATOLOGY & ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS, ANNUAL SCIENTIFIC MEETING, JOHN WILEY & SONS, INC, US; ATLANTA, GEORGIA, USA, vol. 62, no. Suppl. 10, 1 October 2010 (2010-10-01), XP008147986, ISSN: 0004-3591, DOI: 10.1002/ART.30166 [retrieved on 2010-12-28] (B1)